As part of the delegation led by Business France, Hemerion is participating in the new edition of BIO held in Boston: an opportunity to forge new scientific partnerships and accelerate the development of its therapeutic innovations, particularly in the treatment of brain cancer. Hemerion will participate in Bio Convention 2025, held in Boston from June …

In the first quarter of 2025, Hemerion completed a Series A funding round totaling over €6.5 million. This new fundraising follows initial rounds in 2022 and 2023, which raised a total of €5.5 million, bringing the total amount raised by Hemerion since its creation in late 2020 to over €14 million. Hemerion’s successful funding round …

Hemerion has been awarded the ISO 13485:2016 certification for its Medical Device Quality Management System by the British Standard Institute (BSI). This internationally recognized standard demonstrates the company’s commitment to maintaining a robust quality management system for the design, development, production, and distribution of its photonic medical devices. The ISO 13485 certification signifies that Hemerion …

The FDA has granted Fast Track designation to Hemerion Therapeutics for its Pentalafen® / Heliance® combination therapy to improve outcomes in the treatment of glioblastoma. This decision means that clinical development can be accelerated and the product can be brought to the US market more quickly. Fast track status is granted by the FDA to …

Awards, clinical advances, funding, innovation: the year 2024 was marked by significant progress in our fight against brain cancer. January February March April May June July October November December

On December 2, 2024, Hemerion presented its Pentalafen/Heliance technology at the CHU x Healtech Connection Day event, which brings together hospital professionals and healthcare entrepreneurs. The “CHU X HealthTech Connection Day”, whose third edition took place on December 2, 2024 at the Lille Grand Palais, is a key event for healthcare innovation in France. Co-organized …

On 3 December 2024, Hemerion took part in the joint edition of MedFIT and BioFIT held in Lille. This event was an opportunity for our team to develop its partnerships and present its latest advances. Hemerion left the event with a new success: the prize for the Most Innovative European start-up, awarded at the end …

Hemerion, a company specializing in the development of innovative cancer therapies, won the INPI 2024 Trophy in the “Partnership Research” category on November 27, 2024. Created in 1991, this prestigious competition, organized by the French National Institute of Industrial Property (INPI), rewards exemplary companies in terms of their intellectual property strategy. This trophy rewards the …

Hemerion once again supports the second French National Brain Cancer Day organized by five patient associations in Paris on December 2nd. The French National Brain Cancer Day took place on December 2, 2024 in Paris. This second edition is once again an opportunity to mobilize the general public, health professionals and institutions to improve the …

Hemerion, a company specializing in the development of innovative cancer therapies, has been selected as a finalist for the INPI 2024 trophies in the “Partnership Research” category. Created in 1991, this prestigious competition organized by the Institut National de la Propriété Industrielle (INPI) rewards companies with exemplary intellectual property strategies. This selection rewards the work …